Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01918995 · ClinicalTrials.gov registry record · Phase 1
Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01918995 is a Phase 1 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 36 participants.
The verdict
NCT01918995, a Phase 1 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study is to determine the safety, tolerability, and pharmacokinetics of two or three repeat intravenous (IV) bolus doses of regadenoson administered 10 minutes apart in healthy supine subjects.
Interventions
- DRUG Placebo
- DRUG Regadenoson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-05 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01918995
The ClinicalTrials.gov registry entry for NCT01918995 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01918995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01918995 about?
NCT01918995 is a clinical study titled "Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects". This study is to determine the safety, tolerability, and pharmacokinetics of two or three repeat intravenous (IV) bolus doses of regadenoson administered 10 minutes apart in healthy supine subjects.
What is the current status of trial NCT01918995?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2013-05. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01918995?
The interventions under investigation include: Placebo (DRUG), Regadenoson (DRUG).
Who is sponsoring clinical trial NCT01918995?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.